Quetiapine-Lurasidone

Quetiapine
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AH04
Medscape Quetiapine
PubChem 5002
PubMed Quetiapine
Drugs.com quetiapine-fumarate
Kompas (Dutch) Quetiapine
Wikipedia Quetiapine
Lurasidone
Type Antipsychotic
Group Atypical AP
links
Medscape Lurasidone
PubMed Lurasidone
Kompas (Dutch) Lurasidone
Wikipedia Lurasidone

Switch medication from Quetiapine to Lurasidone.

Nietinrijdenbord.png Stop Quetiapine
  • Day 1-4: approx. 75% of initial dose
  • Day 5-8: approx. 50% of initial dose
  • Day 9-12: approx. 25% of initial dose
  • Day 13: stop
Eenrichtingbord.png Start Lurasidone
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
Infobord.png More information
  • More information on switching to lurasidon: see reference. [5]
    Switchstandaardup en down.jpg
Nietinrijdenbord.png — Quetiapine
Eenrichtingbord.png — Lurasidone


  1. ↑ 1.01.11.2 KNMP; Informatorium Medicamentorum 2015; Monografie "quetiapine" (Dutch)
  2. ↑ NVZA; Toxicology.org; Monografie 73 (dutch)
  3. ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
  4. ↑ Drugs.com quetiapine-fumarate
  5. ↑ McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.